Compare GBTG & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBTG | LQDA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2020 | 2020 |
| Metric | GBTG | LQDA |
|---|---|---|
| Price | $5.56 | $37.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $9.40 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 173.33 | 51.81 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $2,718,000,000.00 | $158,320,000.00 |
| Revenue This Year | $22.44 | $265.61 |
| Revenue Next Year | $4.36 | $62.82 |
| P/E Ratio | $25.36 | ★ N/A |
| Revenue Growth | 12.17 | ★ 1031.18 |
| 52 Week Low | $4.96 | $11.26 |
| 52 Week High | $8.64 | $46.67 |
| Indicator | GBTG | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.41 | 55.12 |
| Support Level | $5.29 | $31.75 |
| Resistance Level | $5.86 | $39.19 |
| Average True Range (ATR) | 0.19 | 1.80 |
| MACD | 0.04 | 0.20 |
| Stochastic Oscillator | 59.20 | 77.42 |
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.